Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 1999 December;51(4) > Minerva Urologica e Nefrologica 1999 December;51(4):191-5

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

ORIGINAL ARTICLES   

Minerva Urologica e Nefrologica 1999 December;51(4):191-5

Copyright © 2000 EDIZIONI MINERVA MEDICA

language: English

Treatment of benign prostatic hyperplasia with transurethral electrovaporization of the prostate (TUVP) using Vaportrode VE-B. Two years follow-up

Diana M., Schettini M., Gallucci M.

From the Department of Urology “Cristo Re” Hospital - Rome


PDF


Back­ground. The ­authors ­report ­their expe­ri­ence on trans­urethral vapor­iza­tion of the pros­tate ­with Vapor­tode for the treat­ment of BPH.
­Methods. In Jan­uary 1996 we ­treated 24 ­patients suf­fering ­from cer­vico-ure­thral obstruc­tion ­caused by BPH ­with elec­tro­vap­or­iza­tion of the pros­tate ­using a ­cutting cur­rent of ­between 180 and 250 ­Watts (­average 200 ­Watts). Exclu­sion cri­teria was: PSA>3 ng/ml. The cath­eter was ­removed ­after 24 ­hours. ­Follow-up of all ­patients is 27 ­months. ­Twenty-­three ­patients ­were eval­u­ated.
­Results. ­Results at ­follow-up ­were; ­mean max­imum ­flow (­Qmax) 9.31 ml/sec pre­op­er­a­tive was 19.5 ml/sec ­after 6 ­months, 18.3 ­after 12 ­months and 18.0 ­after 24 ­months; ­mean ­symptom ­score ­decreased ­from 18.1 to 10.4 ­after 6 ­months, to 3.2 ­after 12 ­months and to 4.8 ­after 24 ­months; QL ­index ­decreased ­from 4.6 to 2.3 at 6 ­months, to 1.4 ­after 12 ­months and 24 ­months; the ­average ­avoiding pres­sure ­decreased ­from 62.8 cm/H2O to 23.2 cm/H2O ­after 6 ­months, to 21.2 ­after 12 ­months and to 23.8 ­after 24 ­months. ­There was no ­post ­voiding ­residual ­urine 2 ­days ­after treat­ment in all ­patients.
Con­clu­sions. ­Follow-up ­shows trans­urethral elec­tro­vap­or­iza­tion of the pros­tate is an effi­cient and ­safe tech­nique for treat­ment of BPH.

top of page